Farnesol Inhibits PI3 Kinase Signaling and Inflammatory Gene Expression in Primary Human Renal Epithelial Cells

Area of Science:

• Nephrology
• Pharmacology
• Cell Biology

Background:

• Chronic inflammation and elevated cytokines are hallmarks of chronic kidney disease (CKD) progression, leading to complications and mortality.
• Natural compounds with anti-inflammatory properties are being explored as complementary therapies for CKD.

Purpose of the Study:

• To investigate the potential anti-inflammatory effects of the natural compound farnesol.
• To evaluate farnesol's impact on inflammatory signaling in primary human renal proximal tubule epithelial cells (RPTECs).

Main Methods:

• Farnesol was encapsulated in small unilamellar vesicles (SUVs) to enhance solubility.
• Cell attachment of empty and farnesol-loaded SUVs was confirmed using fluorescent dye.
• Protein, RNA, and phosphorylation arrays were employed to analyze inflammatory signaling pathways in RPTECs.

Main Results:

• Farnesol significantly inhibited TNF-α/IL-1β-induced phosphorylation of the PI3 kinase p85 subunit.
• Farnesol suppressed the transcriptional activation of inflammatory genes including TNFRSF9, CD27, and FAS.
• These findings demonstrate farnesol's ability to modulate key inflammatory mediators in kidney cells.

Conclusions:

• Farnesol exhibits promising anti-inflammatory properties relevant to chronic kidney disease.
• Farnesol's mechanism involves inhibiting the PI3K/Akt pathway and downstream inflammatory gene expression.
• Farnesol represents a potential natural therapeutic agent for managing CKD.